Loading organizations...
§ Private Profile · Paris, Ile-de-France, France
Biotech startup developing small-molecule protein degradation for inflammatory, autoimmune, cancer, viral diseases.
Enodia Therapeutics is a biotechnology company that develops small-molecule therapies targeting the Sec61 translocon to degrade disease-causing secreted and membrane proteins at the point of synthesis. The organization utilizes a specialized technological platform combining proteomics and machine learning to achieve selective protein degradation across multiple therapeutic areas. Its initial drug discovery efforts focus on treating inflammatory and autoimmune diseases, with potential future clinical applications in oncology and viral infections. The startup recently secured €20.7 million, or approximately $25 million, in seed financing through a competitive funding round co-led by Bpifrance, Elaia, and Pfizer Ventures. Operating as a scientific spin-off from the Institut Pasteur, the enterprise was initially incubated by Argobio Studio and is currently advancing its lead program toward preclinical candidate selection. Enodia Therapeutics was founded in 2025 by Caroline Demangel and Yves Ribeill.
Enodia Therapeutics has raised $24.2M across 1 funding round.
Enodia Therapeutics has raised $24.2M in total across 1 funding round.
Enodia Therapeutics has raised $24.2M across 1 funding round. Most recently, it raised $24.2M Seed in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 8, 2026 | $24.2M Seed | Florian Denis, Olivier Martinez | Valentin Tonnel, Daniel Sobral, Investsud, Macsf, Mission BioCapital, Sambrinvest | Announced |
Enodia Therapeutics has raised $24.2M in total across 1 funding round.
Enodia Therapeutics's investors include Florian Denis, Olivier Martinez, Valentin TONNEL, Daniel Sobral, InvestSud, MACSF, Mission BioCapital, Sambrinvest.